Glenmark shares hit 52-week low on USFDA warning letter

Stock Analysis – Know before investing Stock score of Glenmark Pharmaceuticals Ltd moved down by 1 in 3 months on a 10-point scale. Subscribe Now Exclusively for

Stock Analysis Stock score of Glenmark Pharmaceuticals Ltd is 7 on a scale of 10. View Stock Analysis »

New Delhi: Shares oftumbled nearly 10 per cent and hit its 52-week low level on the bourses on Monday after the company received a warning letter from the US health regulator for its Baddi facility in Himachal Pradesh.Shares of the drug firm fell to its 52-week low level of Rs 269.75 on the BSE.Drug firm Glenmark Pharmaceuticals on Saturday said it has received a warning letter from the The United States Food and Drug Administration ( USFDA ) for its Baddi facility in Himachal Pradesh.USFDA had inspected the facility between April 15 and April 20, Glenmark said in a BSE filing on Saturday."The company is committed to work along with the USFDA to implement all the necessary corrective actions required to address the concerns raised in the letter and is in the process of preparing a detailed response to the USFDA within 15 working days," Glenmark said.The shares of the company closed 9.30 per cent lower at Rs 286.30 on BSE.
